![[Pack of 2] Multi Collagen Supplements for Women - 10,000mg Type I, II, III, V & X Hydrolysed Marine Collagen Powder, Bovine Collagen, Egg & Cartilage Collagen Peptides for Skin, Hair, Nails & Joints](https://m.media-amazon.com/images/I/61yBhnLdFNL._AC_SY145_.jpg)
- Benchmark ASINB0D92KGV76
- MarketplaceUK
- Category ID2826488031
- Analyzed Products
- Keywordpersonal care
- Price Range-
- Minimum Net Profit Margin10.00%
- MOQ100
- Est. Purchasing CostNo price data
- Data Date2025-03-26
- Your Budget (for new listing) (CNY)¥500,000.00
Report summary from Keble AI Agent: Listing
结论很明确：这个市场不适合进入，属于停滞型低机会市场，不管是大品牌还是小商家，都不应现在切入。 关键问题不是“还能不能优化”，而是当前样本里没有任何可验证的盈利新品牌，且现有可见品牌 Inspiriko 的两个产品全部不赚钱，说明这里不是增长赛道，而是被低利润和低活跃锁死的赛道。
Recommended Products Features Direction
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
New Brands
VS
Old Brands
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
Old Brands
#Budget Requirement
Listing结论很直接：不建议进入，这个市场对新卖家不友好。 你虽然有50万人民币预算，但当前样本里可识别的可盈利产品占比是0%，新上架产品可盈利占比也是0%；同时核心参考品牌 Inspiriko 的两个样本都不赚钱，且属于老品牌打法，不适合作为小商家成功范本。
Early sourcing + logistics + marketing budget (GBP)N/AExplains the budgetWith all these investments, who has profitable new releases
Alternatives- 单一成分胶原蛋白粉：只选海洋胶原或牛源胶原的基础款，通常比多类型复合配方更便宜，也更容易判断是否适合自己。
- 含胶原蛋白的美肤蛋白粉：如果用户本来就会喝蛋白饮品，可改用带胶原的蛋白粉，把“补胶原+补蛋白”合并，降低购买和使用门槛。
- 维生素C + 生物素基础补充方案：若目标主要是头发、指甲和皮肤，先用更低价、成分更简单的维C/生物素组合替代复杂复合胶原。
- 透明质酸（HA）单方补充剂：对更关注皮肤保湿的人群，可用单一HA产品代替多重胶原组合，通常更直接、剂量更清楚。
- 即饮胶原饮品/小瓶shot：不想冲粉的人可选现成饮品，虽然单次成本可能更高，但更省事、更容易坚持，适合犹豫型用户。
- 高蛋白日常食品方案：例如希腊酸奶、鸡蛋、鱼类、骨汤等，用饮食方式补充蛋白质和胶原相关氨基酸，成本更低、无需额外服用。
Alternative solutions may pose a risk to your investment in certain markets.
#Brands Investment Analysis
Listing这个市场不值得进入，直接判定为不适合。 现有数据几乎只有一个老品牌 Inspiriko，整体可盈利产品比例为0%，新产品可盈利比例也为0%，而且没有任何新品牌、新发布产品或有效的增长趋势，说明不是机会市场，而是停滞市场。
Old brand with the most profitable new productsInspiriko
Recent Monthly Revenue (GBP):-(-)B0D92KGV76 (4.6/5 (22 Reviews))Brand is an old entry in this marketOld ReleaseInsufficient Sales to Meet MOQOld ReleaseNot enough sales volume to meet 100 MOQRecent Monthly Revenue (GBP):-(-)B0DJVGF9DSBrand is an old entry in this marketOld ReleaseInsufficient Sales to Meet MOQOld ReleaseNot enough sales volume to meet 100 MOQ#Differentiations
Unique productsCommon productsDifferentiation:- Product features and designs are too common without differentiation
B0D92KGV76 (4.6/5 (22 Reviews))Brand is an old entry in this marketOld ReleaseInsufficient Sales to Meet MOQOld ReleaseNot enough sales volume to meet 100 MOQSales & BSR
Differentiation:- Product features and designs are too common without differentiation
B0DJVGF9DSBrand is an old entry in this marketOld ReleaseInsufficient Sales to Meet MOQOld ReleaseNot enough sales volume to meet 100 MOQSales & BSR
#Net Profit Margins: All vs New
Listing这个市场不值得进入，结论很直接：不是可行机会，而是低利润、低活跃、近乎无需求验证的高风险市场。 现有样本里，2个产品里有1个已知利润率仅13.35%，另1个只有在极端有利条件下才到12.81%，一旦走海运/更慢补货，直接掉到1.79%~2.33%；而可识别的可盈利率是0%，新上架产品可盈利率也是0%，这说明不是“还能优化一点”的问题，而是市场已经被挤进了低利润区，进入后很难靠正常打法赚钱。
Profitability difficultyUnknown - Insufficient New ReleasesAll products distribution on different profit levels
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%other#Top Products by Net Profit Margin
Top 20 Non-Profitable Products
Products with negative profitability ranked by lowest profit value. Only includes products classified as non-profitable regardless of release date.
B0D92KGV76Inspiriko2024-07-07No£25.99-pcs£-13.35%£-B0DJVGF9DSInspiriko2024-10-11No£--pcs£--%£-No profitable product data available for new products#New Product Success Rates
Listing这个市场不适合进入：样本里没有任何可验证的盈利新品，整体盈利率为0%，新品盈利率也是0%，而且当前抓到的核心品牌 Inspiriko 作为老品牌，2个产品全部亏损，说明这个细分赛道连老玩家都没跑通，已经是明显的高压竞争区。
No data availableNo data availableNo data available#Success Rate by Entry Time
Listing这个市场不值得进入：没有新品牌、没有新发布、可验证的盈利新单为0，已经不是机会市场，而是停滞市场。 目前只能看到一个老品牌 Inspiriko，且它的两个产品都处于非盈利/无活跃销售状态；这代表连老玩家都没跑通，用户的 50万CNY 预算也没有对应的有效切入样本可参考。
How many products released each year
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
How many products released each month
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
#Net Profit Margins by Entry Time
Different profit ratios of products released in year
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2022 0 0 0 0 0 0 0 0 2023 0 0 0 0 0 0 0 0 2024 0 0 0 0 0 0 0 0 2025 0 0 0 0 0 0 0 0 2026 0 0 0 0 0 0 0 0 ≥ 10% Profitable< 10% UnprofitableUnidentifiableDifferent profit ratios of products released in month
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2025/7 0 0 0 0 0 0 0 0 2025/8 0 0 0 0 0 0 0 0 2025/9 0 0 0 0 0 0 0 0 2025/10 0 0 0 0 0 0 0 0 2025/11 0 0 0 0 0 0 0 0 2025/12 0 0 0 0 0 0 0 0 2026/1 0 0 0 0 0 0 0 0 2026/2 0 0 0 0 0 0 0 0 2026/3 0 0 0 0 0 0 0 0 2026/4 0 0 0 0 0 0 0 0 2026/5 0 0 0 0 0 0 0 0 2026/6 0 0 0 0 0 0 0 0 ≥ 10% Profitable< 10% UnprofitableUnidentifiable#Case Study
Success Cases